These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 16140010)

  • 21. Synthesis and activity of 1,3,5-triphenylimidazolidine-2,4-diones and 1,3,5-triphenyl-2-thioxoimidazolidin-4-ones: characterization of new CB1 cannabinoid receptor inverse agonists/antagonists.
    Muccioli GG; Wouters J; Charlier C; Scriba GK; Pizza T; Di Pace P; De Martino P; Poppitz W; Poupaert JH; Lambert DM
    J Med Chem; 2006 Feb; 49(3):872-82. PubMed ID: 16451053
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis, cannabinoid receptor affinity, and molecular modeling studies of substituted 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides.
    Silvestri R; Cascio MG; La Regina G; Piscitelli F; Lavecchia A; Brizzi A; Pasquini S; Botta M; Novellino E; Di Marzo V; Corelli F
    J Med Chem; 2008 Mar; 51(6):1560-76. PubMed ID: 18293908
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors.
    Huffman JW; Padgett LW; Isherwood ML; Wiley JL; Martin BR
    Bioorg Med Chem Lett; 2006 Oct; 16(20):5432-5. PubMed ID: 16889960
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and SAR of novel imidazoles as potent and selective cannabinoid CB2 receptor antagonists with high binding efficiencies.
    Lange JH; van der Neut MA; Wals HC; Kuil GD; Borst AJ; Mulder A; den Hartog AP; Zilaout H; Goutier W; van Stuivenberg HH; van Vliet BJ
    Bioorg Med Chem Lett; 2010 Feb; 20(3):1084-9. PubMed ID: 20031412
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potent cannabinergic indole analogues as radioiodinatable brain imaging agents for the CB1 cannabinoid receptor.
    Deng H; Gifford AN; Zvonok AM; Cui G; Li X; Fan P; Deschamps JR; Flippen-Anderson JL; Gatley SJ; Makriyannis A
    J Med Chem; 2005 Oct; 48(20):6386-92. PubMed ID: 16190764
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain.
    Diaz P; Xu J; Astruc-Diaz F; Pan HM; Brown DL; Naguib M
    J Med Chem; 2008 Aug; 51(16):4932-47. PubMed ID: 18666769
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diarylimidazolyl oxadiazole and thiadiazole derivatives as cannabinoid CB1 receptor antagonists.
    Kim JY; Seo HJ; Lee SH; Jung ME; Ahn K; Kim J; Lee J
    Bioorg Med Chem Lett; 2009 Jan; 19(1):142-5. PubMed ID: 19022666
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and pharmacology of 11-nor-1-methoxy-9-hydroxyhexahydrocannabinols and 11-nor-1-deoxy-9-hydroxyhexahydrocannabinols: new selective ligands for the cannabinoid CB2 receptor.
    Marriott KS; Huffman JW; Wiley JL; Martin BR
    Bioorg Med Chem; 2006 Apr; 14(7):2386-97. PubMed ID: 16321538
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Probing the cannabinoid CB1/CB2 receptor subtype selectivity limits of 1,2-diarylimidazole-4-carboxamides by fine-tuning their 5-substitution pattern.
    Lange JH; van der Neut MA; Borst AJ; Yildirim M; van Stuivenberg HH; van Vliet BJ; Kruse CG
    Bioorg Med Chem Lett; 2010 May; 20(9):2770-5. PubMed ID: 20363132
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tricyclic pyrazoles. Part 6. Benzofuro[3,2-c]pyrazole: a versatile architecture for CB2 selective ligands.
    Pinna G; Loriga G; Lazzari P; Ruiu S; Falzoi M; Frau S; Pau A; Murineddu G; Asproni B; Pinna GA
    Eur J Med Chem; 2014 Jul; 82():281-92. PubMed ID: 24922543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bioisosteric replacements of the pyrazole moiety of rimonabant: synthesis, biological properties, and molecular modeling investigations of thiazoles, triazoles, and imidazoles as potent and selective CB1 cannabinoid receptor antagonists.
    Lange JH; van Stuivenberg HH; Coolen HK; Adolfs TJ; McCreary AC; Keizer HG; Wals HC; Veerman W; Borst AJ; de Looff W; Verveer PC; Kruse CG
    J Med Chem; 2005 Mar; 48(6):1823-38. PubMed ID: 15771428
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis and biological evaluation of new N-alkyl 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides as cannabinoid receptor ligands.
    Silvestri R; Ligresti A; La Regina G; Piscitelli F; Gatti V; Lavecchia A; Brizzi A; Pasquini S; Allarà M; Fantini N; Carai MA; Bigogno C; Rozio MG; Sinisi R; Novellino E; Colombo G; Di Marzo V; Dondio G; Corelli F
    Eur J Med Chem; 2010 Dec; 45(12):5878-86. PubMed ID: 20943290
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and SAR of 1,4,5,6-tetrahydropyridazines as potent cannabinoid CB1 receptor antagonists.
    Lange JH; den Hartog AP; van der Neut MA; van Vliet BJ; Kruse CG
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5675-8. PubMed ID: 19699640
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis and pharmacological evaluation of novel 4-alkyl-5-thien-2'-yl pyrazole carboxamides.
    Lazzari P; Pau A; Tambaro S; Asproni B; Ruiu S; Pinna G; Mastinu A; Curzu MM; Reali R; Bottazzi ME; Pinna GA; Murineddu G
    Cent Nerv Syst Agents Med Chem; 2012 Dec; 12(4):254-76. PubMed ID: 22931442
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one (PF-514273), a novel, bicyclic lactam-based cannabinoid-1 receptor antagonist for the treatment of obesity.
    Dow RL; Carpino PA; Hadcock JR; Black SC; Iredale PA; DaSilva-Jardine P; Schneider SR; Paight ES; Griffith DA; Scott DO; O'Connor RE; Nduaka CI
    J Med Chem; 2009 May; 52(9):2652-5. PubMed ID: 19351113
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tetrazole-biarylpyrazole derivatives as cannabinoid CB1 receptor antagonists.
    Kang SY; Lee SH; Seo HJ; Jung ME; Ahn K; Kim J; Lee J
    Bioorg Med Chem Lett; 2008 Apr; 18(7):2385-9. PubMed ID: 18337096
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Suppression of food intake and food-reinforced behavior produced by the novel CB1 receptor antagonist/inverse agonist AM 1387.
    McLaughlin PJ; Qian L; Wood JT; Wisniecki A; Winston KM; Swezey LA; Ishiwari K; Betz AJ; Pandarinathan L; Xu W; Makriyannis A; Salamone JD
    Pharmacol Biochem Behav; 2006 Mar; 83(3):396-402. PubMed ID: 16616951
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Substituted pyrimidines as cannabinoid CB1 receptor ligands.
    Kim MJ; Kim JY; Seo HJ; Lee J; Lee SH; Kim MS; Kang J; Kim J; Lee J
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4692-7. PubMed ID: 19596576
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Arylsulfonamide CB2 receptor agonists: SAR and optimization of CB2 selectivity.
    Ermann M; Riether D; Walker ER; Mushi IF; Jenkins JE; Noya-Marino B; Brewer ML; Taylor MG; Amouzegh P; East SP; Dymock BW; Gemkow MJ; Kahrs AF; Ebneth A; Löbbe S; O'Shea K; Shih DT; Thomson D
    Bioorg Med Chem Lett; 2008 Mar; 18(5):1725-9. PubMed ID: 18255291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of CoMFA and CoMSIA models of affinity and selectivity for indole ligands of cannabinoid CB1 and CB2 receptors.
    De Freitas GB; da Silva LL; Romeiro NC; Fraga CA
    Eur J Med Chem; 2009 Jun; 44(6):2482-96. PubMed ID: 19249138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.